What Celltrion Healthcare UK Ltd does

Celltrion Healthcare UK Ltd is a UK-registered private limited company and wholly-owned subsidiary of Celltrion, Inc., a South Korean biopharmaceutical group headquartered in Incheon. Founded in 2018 and headquartered at The Charter Building, Uxbridge, Berkshire, the entity operates with a headcount of approximately 25 employees. The company distributes biosimilars for the treatment of oncology, haematology, and autoimmune diseases, functioning as the UK market-access vehicle within Celltrion's global pharmaceutical distribution platform. The UK subsidiary derives revenue through biosimilar product distribution to healthcare organisations (hospitals, clinics, and healthcare systems), healthcare professionals (doctors, pharmacists, and nurses), and patient organisations, with direct field sales supported by global partner and subsidiary infrastructure that spans more than 100 countries.

The UK entity does not enumerate specific product SKUs on its domestic website, instead routing users to the Medicines.org.uk database for patient information leaflets and summary of product characteristics. There is no disclosed proprietary technology, no mobile applications, no public APIs or SDKs, and no identified AI/ML components; the business is fundamentally a regulated pharmaceutical distribution operation rather than a technology or platform business. Customer engagement is driven through the corporate website, dedicated email channels ([email protected], [email protected], [email protected], [email protected]), phone lines, and ABPI-aligned transparency reporting via Disclosure UK.

The company has no independent funding history, no acquisitions, no patents or trademarks, and no awards documented in the input. Its commercial identity is anchored to the parent group's brand, its ABPI Code of Practice commitment, and its regulatory/licensing posture under EMA and MHRA frameworks. Strategically, the UK subsidiary's role is best understood as a localised distribution and pharmacovigilance front for Celltrion's group-level biosimilar pipeline, with strategic significance tied to continued NHS and private healthcare-system adoption of biosimilars in the UK.

Name

Celltrion Healthcare UK Ltd

Legal name

Celltrion Healthcare United Kingdom Limited

Website

https://celltrionhealthcare.co.uk

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Celltrion Healthcare UK Ltd is a UK-registered, wholly-owned subsidiary of South Korea's Celltrion, Inc. Founded in 2018 and headquartered in Uxbridge, it distributes biosimilars for oncology, haematology, and autoimmune diseases to UK healthcare organisations and professionals.

Ownership category

akta.pro rank

Product category

Biosimilar Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Biosimilar pharmaceuticals
• Oncology treatments
• Autoimmune therapies
• Haematology biosimilars
• Pharmaceutical distribution

Headquarters

HQ city

Uxbridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Biosimilar Distribution: Celltrion Healthcare distributes biosimilars globally for the treatment of oncology, haematology and autoimmune diseases. As a pharmaceutical sales and distribution company, revenue is generated through product distribution to healthcare systems and providers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Celltrion Healthcare UK Ltd distributes biosimilar pharmaceuticals for the treatment of oncology, haematology, and autoimmune diseases within the United Kingdom. As a UK regional subsidiary of South Korea-based Celltrion, Inc., it operates as the local commercial arm for biosimilar products developed by the parent group, supplying hospitals, clinics, and healthcare professionals with cost-effective alternatives to originator biologics. The UK website does not enumerate individual branded products; detailed product information is routed through the Medicines.org.uk database.

Product overview

Celltrion Healthcare UK Ltd is a biopharmaceutical company specializing in the distribution of biosimilars for the treatment of oncology, haematology, and autoimmune diseases. The company operates as part of the global Celltrion group and provides biosimilar treatment options that offer patients alternative therapies and cost-effective solutions for healthcare systems. Specific product names are not enumerated on the UK website; the Products page directs users to the Medicines.org.uk database for detailed product information including Patient Information Leaflets (PILs) and Summary of Product Characteristics (SmPCs).

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Global sales market coverage in over 100 countries
• +2 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Global Partners NetworkcoreChannel Partner/ Reseller/ DistributorCelltrion Healthcare operates with over 20 global partners to distribute biosimilars across over 100 countries worldwide.
• Association of the British Pharmaceutical Industry (ABPI)coreStrategic or Co-development PartnerCelltrion Healthcare UK is committed to working within the ABPI Code of Practice, maintaining transparency in interactions with healthcare professionals and organisations.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Amgen: Originator biologic manufacturer that has also launched multiple biosimilars (e.g., AMGEVITA, KANJINTI) competing with Celltrion in UK markets. Amgen's broader portfolio and originator heritage make it a broad incumbent competitor rather than a pure biosimilar peer.
• Pfizer: Operates a significant biosimilar portfolio (via Hospira legacy) across immunology and oncology with UK presence. Pfizer is a broad incumbent with multiple business lines beyond biosimilars but competes directly in NHS biosimilar tenders.
• Teva Pharmaceutical Industries: Global generics and biosimilars manufacturer with UK distribution of biosimilars (trastuzumab, rituximab) competing in the same NHS indications. Functions as a broad incumbent with diversified product lines.

Direct peers

• Samsung Bioepis: Major biosimilar developer with UK-approved products in oncology (trastuzumab, bevacizumab) and immunology (etanercept, adalimumab) that directly compete with Celltrion's UK offerings in the same therapeutic areas.
• Viatris: Formed via Mylan-Upjohn merger, Viatris distributes biosimilars (including biosimilar insulin and oncology biologics) globally with active UK operations, positioning it as a direct competitor to Celltrion Healthcare UK in biosimilar distribution.
• Organon & Co. Post-Merck spinoff focused on women's health and biosimilars, with UK operations distributing biosimilars that overlap with Celltrion's therapeutic areas. A direct competitor in NHS biosimilar procurement.
• Biocon Biologics: India-based biosimilar developer with UK-approved products (trastuzumab, pegfilgrastim) and an active UK commercial presence targeting the same oncology and immunology indications as Celltrion's UK portfolio.
• Sandoz (Novartis): The global market leader in biosimilars, distributing across oncology, immunology, and haematology indications that overlap directly with Celltrion's UK portfolio. Sandoz operates UK distribution and is the most direct head-to-head competitor in NHS biosimilar tenders.

Emerging players

• Alvotech: Iceland-headquartered pure-play biosimilar developer focused on immunology, oncology, and ophthalmology molecules overlapping Celltrion's UK portfolio. A emerging challenger in biosimilar development and distribution.

Others

• Celltrion, Inc. South Korean parent company that develops and manufactures the biosimilars distributed by Celltrion Healthcare UK Ltd. Listed as a related party rather than a competitor; included to contextualize the parent's role and scale relative to the UK subsidiary.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/celltrion-healthcare-uk-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celltrion Healthcare UK Ltd